NCT01054222 - Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Urinary Bladder, Overactive

Interventions

DRUG

Fesoterodine

Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)

DRUG

Fesoterodine

Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)

Trial Locations (3)

1990-273

Centro de Avaliação Geriátrica, Lisbon

4099-005

Hospital Ordem do Carmo, Porto

4200-319

Hospital de São João, Porto